Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up.
Romero-Aroca PedroSofia de la Riva-FernandezAida Valls-MateuRamon Sagarra-AlamoAntonio Moreno-RibasNuria SolerDomenec PuigPublished in: BMC ophthalmology (2016)
Screening for diabetic retinopathy every 2.5 years is cost-effective, but should be adjusted to a patient's personal risk factors. Treatment with anti-VEGF for DMO has increased costs, but the cost-utility increases to 0.21 QALY per patient.